

# Simon R J Taylor

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2983417/publications.pdf>

Version: 2024-02-01

103  
papers

3,046  
citations

126708  
33  
h-index

174990  
52  
g-index

104  
all docs

104  
docs citations

104  
times ranked

2822  
citing authors

#	ARTICLE	IF	CITATIONS
1	Understanding uveitis: The impact of research on visual outcomes. <i>Progress in Retinal and Eye Research</i> , 2011, 30, 452-470.	7.3	272
2	Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1540-1547.	6.7	182
3	Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis. <i>Ophthalmology</i> , 2014, 121, 2387-2392.	2.5	180
4	Intraocular Methotrexate in the Treatment of Uveitis and Uveitic Cystoid Macular Edema. <i>Ophthalmology</i> , 2009, 116, 797-801.	2.5	124
5	Treatment with Repeat Dexamethasone Implants Results in Long-Term Disease Control in Eyes with Noninfectious Uveitis. <i>Ophthalmology</i> , 2014, 121, 1649-1654.	2.5	120
6	P2X7 Deficiency Attenuates Renal Injury in Experimental Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1275-1281.	3.0	105
7	BehÃ§et Disease: Visual Prognosis and Factors Influencing the Development of Visual Loss. <i>American Journal of Ophthalmology</i> , 2011, 152, 1059-1066.	1.7	97
8	New Developments in Corticosteroid Therapy for Uveitis. <i>Ophthalmologica</i> , 2010, 224, 46-53.	1.0	86
9	Endophthalmitis following 25-gauge vitrectomy. <i>Eye</i> , 2005, 19, 1228-1229.	1.1	79
10	FACTORS DETERMINING VISUAL OUTCOME IN ENDOGENOUS CANDIDA ENDOPHTHALMITIS. <i>Retina</i> , 2012, 32, 1129-1134.	1.0	77
11	INTRAOULAR METHOTREXATE CAN INDUCE EXTENDED REMISSION IN SOME PATIENTS IN NONINFECTIOUS UVEITIS. <i>Retina</i> , 2013, 33, 2149-2154.	1.0	75
12	Sequential Shrinkage and Swelling Underlie P2X7-Stimulated Lymphocyte Phosphatidylserine Exposure and Death. <i>Journal of Immunology</i> , 2008, 180, 300-308.	0.4	68
13	Associations among Visual Acuity and Vision- and Health-Related Quality of Life among Patients in the Multicenter Uveitis Steroid Treatment Trial. , 2012, 53, 1169.		63
14	Pegylated interferon-Î±-2b reduces corticosteroid requirement in patients with BehÃ§et's disease with upregulation of circulating regulatory T cells and reduction of Th17. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1138-1144.	0.5	60
15	Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries. <i>British Journal of Ophthalmology</i> , 2019, 103, 1072-1077.	2.1	60
16	The Impact of Macular Edema on Visual Function in Intermediate, Posterior, and Panuveitis. <i>Ocular Immunology and Inflammation</i> , 2012, 20, 171-181.	1.0	54
17	Long-term Outcomes of Rituximab Therapy in Ocular Granulomatosis with Polyangiitis. <i>Ophthalmology</i> , 2015, 122, 1262-1268.	2.5	53
18	Clinical and Imaging Features Predictive of Orbital Granulomatosis with Polyangiitis and the Risk of Systemic Involvement. <i>Ophthalmology</i> , 2014, 121, 1304-1309.	2.5	52

#	ARTICLE	IF	CITATIONS
19	Long-term Clinical and Anatomic Outcome of Birdshot Chorioretinopathy. <i>JAMA Ophthalmology</i> , 2014, 132, 57.	1.4	50
20	Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. <i>British Journal of Ophthalmology</i> , 2013, 97, 1040-1044.	2.1	48
21	Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE). <i>Acta Ophthalmologica</i> , 2018, 96, e10-e18.	0.6	48
22	Valacyclovir in the treatment of acute retinal necrosis. <i>BMC Ophthalmology</i> , 2012, 12, 48.	0.6	46
23	Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. <i>Acta Ophthalmologica</i> , 2012, 90, e323-5.	0.6	46
24	Hypotony in Patients with Uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. <i>Ocular Immunology and Inflammation</i> , 2012, 20, 104-112.	1.0	45
25	Dexamethasone Implant in Pediatric Uveitis. <i>Ophthalmology</i> , 2012, 119, 2412-2412.e2.	2.5	45
26	Local therapies for inflammatory eye disease in translation: past, present and future. <i>BMC Ophthalmology</i> , 2013, 13, 39.	0.6	45
27	Lymphocytes from P2X7-deficient mice exhibit enhanced P2X7responses. <i>Journal of Leukocyte Biology</i> , 2009, 85, 978-986.	1.5	43
28	Regulatory T Cells Are Resistant to Apoptosis via TCR but Not P2X7. <i>Journal of Immunology</i> , 2007, 178, 3474-3482.	0.4	42
29	The ocular manifestations of inflammatory bowel disease. <i>Current Opinion in Ophthalmology</i> , 2006, 17, 538-544.	1.3	37
30	Rituximab in Refractory Ophthalmic Wegener's Granulomatosis. <i>Ophthalmology</i> , 2011, 118, 2498-2503.	2.5	37
31	Review and update of intraocular therapy in noninfectious uveitis. <i>Current Opinion in Ophthalmology</i> , 2011, 22, 517-522.	1.3	37
32	Uveitis as a Result of MAP Kinase Pathway Inhibition. <i>Case Reports in Ophthalmology</i> , 2013, 4, 279-282.	0.3	36
33	Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial. <i>American Journal of Ophthalmology</i> , 2015, 160, 1133-1141.e9.	1.7	35
34	A Case of Optic Neuropathy after Short-term Linezolid Use in a Patient with Acute Lymphocytic Leukemia. <i>Clinical Infectious Diseases</i> , 2009, 48, e73-e74.	2.9	33
35	Intravitreal Methotrexate in Uveitis. <i>Ophthalmology</i> , 2012, 119, 878-879.	2.5	33
36	Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. <i>Ophthalmology and Therapy</i> , 2016, 5, 47-61.	1.0	31

#	ARTICLE	IF	CITATIONS
37	Azathioprine in the Management of Autoimmune Uveitis. <i>Ocular Immunology and Inflammation</i> , 2008, 16, 161-165.	1.0	28
38	Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery. <i>Acta Ophthalmologica</i> , 2012, 90, e572-3.	0.6	25
39	Birdshot uveitis: current and emerging treatment options. <i>Clinical Ophthalmology</i> , 2013, 8, 73.	0.9	23
40	Evaluation of Retinal Nerve Fiber Layer Thickness in Eyes With Hypertensive Uveitis. <i>JAMA Ophthalmology</i> , 2014, 132, 859.	1.4	23
41	Outcomes of Changing Immunosuppressive Therapy after Treatment Failure in Patients with Noninfectious Uveitis. <i>Ophthalmology</i> , 2014, 121, 1119-1124.	2.5	23
42	Recurrent Anterior Uveitis in Patients With Vogt-Koyanagi-Harada Syndrome. <i>JAMA Ophthalmology</i> , 2004, 122, 922.	2.6	22
43	Can Rituximab Induce Long-Term Disease Remission in Patients with Intra-Ocular Non-Infectious Inflammation?. <i>Ophthalmologica</i> , 2013, 230, 109-115.	1.0	20
44	Histopathological features predictive of a clinical diagnosis of ophthalmic granulomatosis with polyangiitis (GPA). <i>International Journal of Clinical and Experimental Pathology</i> , 2012, 5, 684-9.	0.5	19
45	Corticosteroid-Sparing Agents: New Treatment Options. <i>Developments in Ophthalmology</i> , 2012, 51, 47-56.	0.1	18
46	Birdshot chorioretinopathy. <i>Current Opinion in Ophthalmology</i> , 2014, 25, 488-494.	1.3	18
47	Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: A retrospective cohort study establishing clinical risk and ophthalmic disease burden. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 602-608.	1.2	18
48	Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression. <i>JAMA Ophthalmology</i> , 2019, 137, 564.	1.4	17
49	Combined Infliximab and Rituximab in Necrotising Scleritis. <i>Case Reports in Ophthalmology</i> , 2012, 3, 286-290.	0.3	16
50	Interferon-alpha in the management of patients with BehÃ§et's disease. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2008, 69, 575-579.	0.2	14
51	Bilateral Sequential Non-Arteritic Anterior Ischaemic Optic Neuropathy Following Repeat Influenza Vaccination. <i>Case Reports in Ophthalmology</i> , 2014, 5, 267-269.	0.3	14
52	Prevalence and causes of phthisis bulbi in a uveitis clinic. <i>Acta Ophthalmologica</i> , 2012, 90, e417-8.	0.6	13
53	Another case of PORN (bilateral progressive outer retinal necrosis) after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006, 37, 113-114.	1.3	12
54	Anaesthesia and saccadic eye movements. <i>Anaesthesia</i> , 2000, 55, 877-882.	1.8	11

#	ARTICLE	IF	CITATIONS
55	Phacoemulsification in Vitrectomized Eyes under Topical Anesthesia. European Journal of Ophthalmology, 2007, 17, 336-340.	0.7	10
56	Intraocular pressure elevation in uveitis. Expert Review of Ophthalmology, 2012, 7, 45-59.	0.3	10
57	Rhizobium radiobacter Endophthalmitis following Intravitreal Ranibizumab Injection. Case Reports in Ophthalmology, 2012, 3, 283-285.	0.3	9
58	Tissue Interleukin-17 and Interleukin-23 as Biomarkers for Orbital Granulomatosis with Polyangiitis. Ophthalmology, 2015, 122, 2140-2142.	2.5	9
59	Intravitreal bevacizumab injections for diabetic macular edema &ndash; predictors of response: a retrospective study. Clinical Ophthalmology, 2016, Volume 10, 2093-2098.	0.9	9
60	The Use of Sustained Release Intravitreal Steroid Implants in Non-Infectious Uveitis Affecting the Posterior Segment of the Eye. Ophthalmology and Therapy, 2022, 11, 479-487.	1.0	9
61	Effects of low-dose isoflurane on saccadic eye movement generation. Anaesthesia, 1999, 54, 142-145.	1.8	8
62	Topical Prostaglandin Analogues and Conjunctival Inflammation in Uveitic Glaucoma. Open Ophthalmology Journal, 2012, 6, 75-78.	0.1	8
63	Ocular manifestations of Wegenerâ€™s granulomatosis. Expert Review of Ophthalmology, 2011, 6, 541-555.	0.3	7
64	The influence of diabetes mellitus on the management and visual outcome of patients with uveitis. Acta Ophthalmologica, 2014, 92, e329-30.	0.6	6
65	Effects of a low concentration of isoflurane on contrast sensitivity in volunteers. British Journal of Anaesthesia, 1998, 81, 176-179.	1.5	5
66	The eye in cardiac and cardiovascular disease. British Journal of Hospital Medicine, 2003, 64, 299-301.	0.3	5
67	Renal & Ocular Targets for Therapy in Wegeners Granulomatosis. Inflammation and Allergy: Drug Targets, 2009, 8, 70-79.	1.8	5
68	Dexamethasone implants and neovascular glaucoma in central retinal vein occlusion. Acta Ophthalmologica, 2013, 91, e239-40.	0.6	5
69	Safety and Biosimilarity of iorâ®EPOCIM Compared with Eprexâ® Based on Toxicologic, Pharmacodynamic, and Pharmacokinetic Studies in the Spragueâ€“Dawley Rat. Journal of Pharmaceutical Sciences, 2014, 103, 3432-3441.	1.6	5
70	Multiphasic changes in systemic VEGF following intravitreal injections of ranibizumab in a child. Eye, 2015, 29, 569-573.	1.1	5
71	Ocular manifestations of Wegenerâ€™s granulomatosis. Expert Review of Ophthalmology, 2007, 2, 91-103.	0.3	4
72	Uveitis in Rheumatic Diseases. Current Rheumatology Reviews, 2011, 7, 24-38.	0.4	4

#	ARTICLE	IF	CITATIONS
73	The eye in haematological disease. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 691-697.	0.2	4
74	Successful Corticosteroid-Sparing Effect of Rituximab in the Treatment of Refractory Idiopathic Orbital Inflammatory Disease. Case Reports in Ophthalmology, 2013, 4, 216-218.	0.3	4
75	Raised Intraocular Pressure in Nonjuvenile Idiopathic Arthritis-Uveitis Children: Risk Factors and Effect on Retinal Nerve Fiber Layer. Journal of Glaucoma, 2016, 25, 598-604.	0.8	4
76	Of grave concern. Survey of Ophthalmology, 2017, 62, 96-102.	1.7	4
77	Clinical and Molecular Features Associated with Cystic Visceral Lesions in Von Hippel-Lindau Disease. Open Ophthalmology Journal, 2012, 6, 83-85.	0.1	4
78	Dry Eyes in Rheumatic Disease. Current Rheumatology Reviews, 2011, 7, 3-14.	0.4	3
79	Management of branch retinal vein occlusion. British Journal of Hospital Medicine (London, England:) Tj ETQq1 1 0.784314 rgBT /Overlo 0.2		
80	Reply to Cleveland and Gelfand. Clinical Infectious Diseases, 2009, 49, 646-646.	2.9	2
81	The eye in virology. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 672-676.	0.2	2
82	Safety and Biosimilarity of iorÂ®LeukoCIM Compared to NeupogenÂ® Based on Toxicity, Pharmacodynamic, and Pharmacokinetic Studies in the Sprague-Dawley Rat. Journal of Pharmaceutical Sciences, 2017, 106, 1475-1481.	1.6	2
83	Safety and effectiveness of the fluocinolone acetonide intravitreal implant (ILUVIEN): 3-year results from the European IRISS registry study. British Journal of Ophthalmology, 2023, 107, 1502-1508.	2.1	2
84	The eye in malignant disease. British Journal of Hospital Medicine, 2003, 64, 177-179.	0.3	1
85	Visual impairment in the elderly. British Journal of Hospital Medicine (London, England: 2005), 2005, 66, 662-663.	0.2	1
86	The eye and phacomatoses. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 677-681.	0.2	1
87	Ocular Vascular Involvement in the Rheumatic Diseases. Current Rheumatology Reviews, 2011, 7, 39-50.	0.4	1
88	Episcleritis and Scleritis in Rheumatic Disease. Current Rheumatology Reviews, 2011, 7, 15-23.	0.4	1
89	Involvement of Orbital Structures in Rheumatic Disease. Current Rheumatology Reviews, 2011, 7, 51-60.	0.4	1
90	The eye in rheumatology. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 682-685.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Treatment of diabetic maculopathy. British Journal of Hospital Medicine (London, England: 2005), 2015, 76, 35-40.	0.2	1
92	Sutureless 25-Gauge Pars Plana Vitrectomy Combined with Retropupillary Fixation of an Iris-Claw Intraocular Lens. Case Reports in Ophthalmology, 2017, 7, 433-439.	0.3	1
93	Ocular Features of Cerebro-Costo-Mandibular Syndrome. Journal of Glaucoma, 2018, 27, e21-e23.	0.8	1
94	Lessons of the month 2: A case of BehÃ§etâ€™s disease: 70% have ophthalmic involvement. Clinical Medicine, 2019, 19, 519-522.	0.8	1
95	Ocular emergencies 2: non-traumatic. British Journal of Hospital Medicine (London, England: 2005), 2009, 70, M54-M58.	0.2	0
96	Ocular emergencies 1: traumatic. British Journal of Hospital Medicine (London, England: 2005), 2009, 70, M36-M37.	0.2	0
97	The eye in renal disease. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, 686-690.	0.2	0
98	Ocular Complications of Drugs Used in Rheumatic Disease. Current Rheumatology Reviews, 2011, 7, 61-68.	0.4	0
99	Editorial [Hot Topic: The Eye in Rheumatological Disease (Guest Editors: Sue Lightman and Simon) Tj ETQq1 1 0.784314 rgBT <sub>0.4</sub> /Overlock		
100	A sore red eye with systemic involvement. BMJ: British Medical Journal, 2012, 344, e1121-e1121.	2.4	0
101	Reply. Retina, 2013, 33, 454-456.	1.0	0
102	Is P2X7 a potential therapeutic target in the treatment of retinal diseases: an animal study. Lancet, The, 2016, 387, S91.	6.3	0
103	Lesson of the month 2: A case of BehÃ§et's disease: 70% have ophthalmic involvement. Clinical Medicine, 2019, .,	0.8	0